Case study · Oncology market access

Designing a Patient Support Program strategy

A strategy assessment for a novel targeted oral oncology therapy in Canada, balancing early patient access, reimbursement objectives and financial risk.

The challenge

Planning access across a complex funding landscape

A manufacturer was preparing for the launch of a novel targeted oral oncology therapy in a complex Canadian reimbursement environment. The client sought a Patient Support Program (PSP) strategy that optimized investment, supported reimbursement navigation, and aligned with broader market access objectives.

  • Variable funding pathways and timelines across Canada
  • Reliance on both public and private payer access mechanisms
  • The need to balance early access, implementation readiness and the stakeholder engagement a PSP can support with a sustainable transition to funded therapy

Back to top ↑

MORSE’s approach

A payer-informed strategy, from assessment to implementation planning

A structured assessment was conducted to design a PSP strategy that balanced early patient access, reimbursement objectives, and financial risk.

  1. Funding pathway assessment

    Mapped anticipated reimbursement pathways and timelines across Canada to identify compassionate supply and co-pay requirements and associated financial risks before and after public funding is established.

  2. PSP design strategy

    Developed a payer-informed PSP framework with clear eligibility criteria, reimbursement navigation services, and transition plans aligned with reimbursement objectives.

  3. Implementation planning

    Assessed stakeholder needs and operational considerations to support implementation across jurisdictions.

  4. Stakeholder mapping

    Mapped stakeholders, from payers to cancer centres, to help the client identify whom to engage and how to engage them.

Back to top ↑

Results and benefits

Results and benefits

  • Improved navigation across public and private access pathways
  • Reduce financial exposure while maximizing impact, payer engagement, and key opinion leader (KOL) and patient satisfaction

Back to top ↑

Why this matters

Build the transition to funded therapy into the strategy

For manufacturers launching oncology therapies in Canada, PSP design decisions can have significant implications for access, financial exposure, and reimbursement readiness.

This case highlights the value of assessing funding pathways, reimbursement timelines, and transition risks early to ensure PSP investments support both near-term access needs and long-term market access objectives.

Related serviceComprehensive Market Access Launch Strategy

Back to case studies

Back to top ↑

Planning a launch or rethinking your PSP?

Connect with MORSE to discuss your Patient Support Program strategy in Canada.

Discuss your PSP strategy